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pneumonia correlates with perivascular
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Abstract
Background: Nonspecific interstitial pneumonia (NSIP) is characterized by interstitial infiltration of T lymphocytes, and
subpopulations of these cells may be associated with the progression of fibrosis. However, few studies evaluate the
correlation of prognosis with this characteristic. Therefore, we performed morphological and quantitative analyses of T
lymphocytes in patients with NSIP and evaluated the relationship between T lymphocytes and prognosis.
Methods: Immunohistochemistry was used to detect the presence of CD4+ and CD8+ T lymphocytes in 55 biopsies
of patients with NSIP to determine the numbers of these T cell subpopulations in lymphoid follicles as well as in
perivascular, interstitial, and peribronchial anatomical compartments. The relationship between CD4+ and CD8+ T
lymphocyte populations and prognosis was analyzed.
Results: The mean age of 55 patients was 48.9 ± 10.5 years, and 36 (65 %) of patients were women. All patients were
followed for a mean duration of 46 ± 25 months. Thirteen (23.6 %) patients died during follow-up. Perivascular CD4+
lymphocyte infiltration (HR, 0.939; 95 % CI, 0.883–0.999; p = 0.048) was an independent risk factor for survival.
Perivascular infiltrates of CD4+ T lymphocytes correlated with survival time (r = 0.270, p = 0.046). Patients with improved
forced vital capacity survived longer and had higher numbers of CD4+ T lymphocytes that infiltrated perivascular
tissue. The densities of CD4+ and CD8+ T lymphocytes infiltrating other tissues were not significantly associated with
survival time.
Conclusions: Perivascular infiltration of CD4+ T lymphocytes in patients with NSIP correlated with prognosis. The
underlying mechanisms are unknown and require further studies.
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Background
Interstitial lung diseases (ILDs) are generally characterized
by the accumulation of inflammatory cells within the lung,
followed by the progressive deposition of extracellular
matrix and subsequent destruction of alveolar airspaces
[1]. The precise role of inflammatory cells in the patho-
genesis of ILD remains poorly understood [2–4], although
evidence indicates that T lymphocytes play an important
role in the initiation and development of pulmonary fibro-
sis [5, 6]. However, few studies evaluate the prognostic sig-
nificance of T lymphocyte subsets in patients with
nonspecific interstitial pneumonia (NSIP) [7]. Therefore,
we hypothesized that patients with NSIP who respond
successfully to corticosteroid therapy harbor different T
lymphocyte subpopulations compared with patients who
do not respond.
To test this hypothesis, we evaluated the distribution
of T lymphocyte subsets in the lung tissues of patients
with NSIP. Using immunohistochemistry, we quantified
the T lymphocyte subsets present in lymphoid follicles
as well as in perivascular, interstitial, and peribronchial
regions and explored the relationship between prognosis
and survival.
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Methods
Study subjects and diagnostic criteria
Between April 2003 and December 2011, 97 patients
from Peking Union Medical College Hospital
(PUMCH) were diagnosed with NSIP according to
analysis of lung biopsies. Fifty-five patients who com-
pleted follow-up by undergoing tests of pulmonary
function tests and computed tomography (CT) of the
chest were included in this study. NSIP was diag-
nosed according to the American Thoracic Society
(ATS)/European Respiratory Society consensus classi-
fication [8, 9]. Patients were not treated with cortico-
steroids or other immunosuppressants before
undergoing a lung biopsy. Connective tissue disease
(CTD) was diagnosed according to the criteria of the
American College of Rheumatology as follows: auto-
antibodies against the nucleus (ANA titer >1:320),
rheumatoid factor, Sjögren’s-syndrome-related antigens
SSA or SSB, Scl-70, Sm, anti-Jo-1, ribonucleoprotein,
or cyclic citrullinated peptide [10–13]. Patients with
NSIP were classified into the groups as follows: (1)
Members of the CTD-NSIP group met the criteria of
the American College of Rheumatology for CTD. (2)
Members of the NSIP-Ab + group had at least one
positive serologic test. (3) Members of the NSIP-Ab–
group were autoantibody negative. We extracted clin-
ical characteristics documented at the time of a pa-
tient’s first visit as follows: age, ethnicity, sex,
symptoms (cough, dyspnea, or wheeze) at the time of
lung biopsy, symptoms or signs of CTD, smoking sta-
tus, physical examination findings, pulmonary func-
tion results, serologic results, and chest CT scan.
Informed consent to use medical records was obtained
from every patient, their guardian, or both when the pa-
tient was admitted to the hospital. The PUMCH Institu-
tional Review Board approved this study (reference
number for ethics approval: 2012–10–312).
Pulmonary physiological assessments
Spirometry, total lung capacity determined using plethys-
mography, forced vital capacity (FVC), and diffusing cap-
acity of the lung for carbon monoxide were measured
according to ATS recommendations [14–16], and the re-
sults are expressed as the percentage of predicted normal
values. Prognosis was described according to FVC 1 year
after steroid therapy. We classified patients as follows:
FVC-group 1, improvement of FVC >10 %; FVC-group 2,
improvement of FVC between 10 % and −10 %; and FVC-
group 3, FVC reduced greater than −10 % [17–20].
High-resolution CT
All patients underwent high-resolution CT (HRCT) of
the chest upon initial evaluation. A radiologist who spe-
cializes in diffuse parenchymal lung disease reviewed the
CT scans. The extent and prevalence of abnormalities
were measured in the areas as follows: (1) from the lung
apex to the carina, (2) from the carina to the upper pul-
monary vein, and (3) from the upper pulmonary vein to
the base of the lung. HRCT images were assessed to de-
termine the extent of parenchymal abnormalities, in-
cluding ground-glass opacity (GGO), reticulation,
honeycombing, consolidation, and emphysema. The ex-
tent of these abnormalities was determined using a 10 %
























Fig. 1 Distribution of T lymphocytes in different regions of lung tissue: CD4+ and CD8 + T lymphocytes decreased gradually in order of Lymphoid
follicle, perivascular, interstitial and peribronchiolar regions. Positively stained of CD4+ and CD8 + T lymphocytes with dark brown staining
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to the manifestations detected using CT 1 year after
steroid therapy. Patients with NSIP were classified as fol-
lows: CT-group 1, improvement of GGO and reticular
opacity >50 %; group, CT-group 2, lesions reduced be-
tween 30 % and 50 %, and CT-group 3, lesions reduced
by <30 % [21–23].
Histology of lung tissue
Two experienced pathologists reviewed independently
the lung biopsy specimens, and the histologic pattern
was assigned according to the consensus opinion. The
pathologists were unaware of the patients’ clinical infor-
mation. The histological patterns of the 55 patients were
classified further, according to criteria proposed by Kat-
zenstein and Fiorelli [24], as cellular, mixed, or fibrotic.
Small airways were defined as those with an internal
diameter <2 mm without cartilage in the airway walls
[25]. Small blood vessels were defined as those with an
internal diameter ≤100 μm [26].
Immunohistochemical analysis of CD4 and CD8
expression in lung tissue
Lung biopsy specimens were fixed in 10 % neutral-
buffered formalin, cut into slices, embedded in paraf-
fin, and cut into 4-μm-thick sections. Paraffin sections
were reacted anti-CD4 (clone SP35, Zeta), and anti-
CD8 (clone EP1150, Zeta) antibodies using the
labeled-streptavidin-biotin complex method. The sec-
tions were deparaffinized, rehydrated with Tris-
Buffered Saline (TBS) (0.005 M Tris, 0.15 M NaCl,
pH 7.6) for 10 min, treated with 3 % hydrogen perox-
ide for 5 min to inhibit endogenous peroxidase activ-
ity, washed in TBS, and incubated with primary
antibodies for 1 h. Immunohistochemical analyses of
CD4 and CD8 expression were performed using the
same tissue sections.
The numbers of dark-brown cells were determined
using a NanoZoomer 2.0-RS Slide Scanning System
(Hamamatsu Photonics KK; Japan Tokyo) and an Any-
micro DSS Pro Image Analysis System (Yu Tian Shi Ji
Wei Ye INC; Beijing, China). The follicles as well as
perivascular, interstitial, and peribronchial regions were
analyzed. The images of CD4+ and CD8+ T lymphocytes
were obtained from the same region of the slide. At least
six high-power fields (magnification × 200; analysis area,
approximately 0.162 mm2) were randomly selected for
each region and used to count the stained cells (Fig. 1).
Treatment and follow up
All patients received a standard initial course of oral pred-
nisone, starting at 0.5 mg/kg/d for 1 month that was ta-
pered every 3 weeks to 5–7.5 mg/d (10 % decrease of the
initial dose every 3 weeks), and maintained at 5–7.5 mg/d.
Patients were treated for 12–18 months. Cyclophospha-
mide was administered concurrently with steroid therapy
at an oral dose of 100 mg/d administered for 3–6 months
to patients diagnosed with CTD-NSIP. Patients under-
went routine examinations every 3–6 months after lung
biopsy and then once each year at the Interstitial Lung
Disease Clinic of PUMCH.
Statistical analysis
All values are expressed as the mean ± standard devi-
ation (SD). Normally distributed data were evaluated
using the t test. The Wilcoxon and Kruskal–Wallis
tests were used to compare two or more non-
normally distributed values, respectively. Fisher’s
Table 1 Clinical features and laboratory findings of patients
with NSIP
NSIP (n = 55)













ESR, mm/h 21.2 ± 19.2
PaO2, mmHg 77.8 ± 12.9
PCO2, mmHg 37.9 ± 8.4
Serological results, N (%)
Anti-nuclear antibody 14 (25.5)
Anti-SSA antibody 3 (5.5)
Anti-neutrophil cytoplasmic antibody 3 (5.5)
Anti-Jo-1 antibody 1 (1.8)
Anti-Scl-70 antibody 1 (1.8)
PFT
TLC, % predicted 76.8 ± 14.1
DLCO, % predicted 56.4 ± 16.8
Baseline chest CT findings, N (%)
Ground glass opacity 34 (61.8)
Patchy opacity 40 (72.7)
Irregular reticular opacity 35 (63.6)
Traction bronchiectasis 17 (30.9)
Pleural thickness 5 (14.6)
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exact test was used to determine differences between
groups. Correlation coefficients were calculated using
the Spearman rank method. Cox multivariate regres-
sion analysis was used to evaluate risk factors of sur-
vival. The times to overall survival were calculated
using the Kaplan–Meier method. The probability
value was obtained using 2-sided tests, and statistical
significance was defined as p < 0.05. SPSS 15.0 (SPSS
for Windows, version 15.0; SPSS Inc., Chicago, IL,
USA) was used for statistical analysis.
Results and discussion
Clinical features and laboratory findings
The clinical, radiological, and physiological measure-
ments obtained at the time of the initial visit are shown
in Table 1. The mean age of 55 patients was 48.9 ±
10.5 years (range, 23–68 years), and 36 patients (65 %)
were women. There were 47 nonsmokers, six former
smokers, and two current smokers. The mean duration
of respiratory symptoms from onset to lung biopsy was
6 months (20.2 ± 50.9 months; range, 0.8–360 months).








Age (years) 50.48 ± 11.73 44.57 ± 8.81 50.50 ± 9.99 0.197
Male (%) 15/21 (71.4 %) 10/14 (71.4 %) 11/20 (55.0 %) 0.468
Duration (months) 12.21 ± 18.06 18.06 ± 30.99 30.20 ± 78.73 0.528
Follow-up time (months) 43.14 ± 23.90 53.43 ± 29.07 44.40 ± 24.01 0.467
Symptoms
Dyspnea 15/21 (71.4 %) 13/14 (92.9 %) 19/20 (95 %) 0.067
Cough 14/21 (66.7 %) 10/14 (71.4 %) 16/20 (80 %) 0.627
Chest pain 2/21 (9.5 %) 1/14 (7.1 %) 1/20 (5 %) 0.856
Dry eyes or dry mouth 2/21 (9.5 %) 1/14 (7.1 %) 0 0.386
Fever 2/21 (9.5 %) 2/14 (14.3 %) 3/20 (15 %) 0.853
Arthralgia 6/21 (28.6 %) 3/14 (21.4 %) 1/20 (5 %) 0.138
Rash 5/21 (23.8 %) 1/14 (7.1 %) 0 0.044
Raynaud’s phenomenon 3/21 (14.3 %) 0 0 0.077
Weight loss 2/21 (9.5 %) 1/14 (7.1 %) 1/20 (5.0 %) 0.856
Signs
Crackles 19/21 (90.5 %) 13/14 (92.9 %) 15/20 (75 %) 0.246
Clubbing 7/21 (33.3 %) 5/14 (35.7 %) 5/20 (25 %) 0.765








ESR, mm/h 16.33 ± 7.69 19.50 ± 12.70 27.45 ± 28.32 0.167
PaO2, mmHg 76.28 ± 14.25 80.67 ± 9.77 77.47 ± 13.52 0.614
PCO2, mmHg 40.20 ± 11.94 36.24 ± 5.57 36.74 ± 4.52 0.292
TLC, % predicted 77.17 ± 15.82 74.42 ± 10.37 77.01 ± 12.70 0.844
DLCO, % predicted 53.54 ± 14.06 56.62 ± 20.86 55.79 ± 8.60 0.893
Chest CT findings at biopsy
Ground glass opacity 15/21 (71.4 %) 6/14 (42.9 %) 13/20 (65.0 %) 0.219
Patchy 16/21 (76.2 %) 10/14 (71.4 %) 14/20 (70.0 %) 0.899
Reticular opacity 12/21 (57.1 %) 11/14 (78.6 %) 12/20 (60.0 %) 0.397
Bronchiectasis 4/21 (19.0 %) 5/14 (35.7 %) 8/20 (40.0 %) 0.315
Pleural thickness 1/21 (4.8 %) 4/14 (28.6 %) 3/20 (15.0 %) 0.147
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All patients were followed for a mean duration of 64.3 ±
26.7 months (range, 14–120 months).
The patients were diagnosed as follows: 21 with
CTD-NSIP (including seven with polymyositis/derm-
atomyositis; seven with rheumatoid arthritis; four with
of Sjögren syndrome; two with systemic sclerosis, and
one with microscopic polyangiitis), 14 with NSIP-Ab
(+), and 20 with NSIP-Ab (−). There were no differ-
ences among the three groups according to age, sex,
cough, and dyspnea. Symptoms of arthralgia, Ray-
naud’s phenomenon, skin rash, and dry eye or mouth
were highly associated with the CTD-NSIP and NSIP-
Ab + groups compared with the NSIP-Ab- group
(Table 2). No differences among the three groups
were noted in arterial blood gas and HRCT findings.
Abnormalities of pulmonary function were similar
among the three groups and were characterized by
restrictive defects with impairment of diffusion
(Table 3). During follow-up, three patients (15 %)
with cellular NSIP died (two from lung infections,
one from liver failure), and six (21 %) and four
(80 %) patients with mixed or fibrotic NSIP, respect-
ively, died from progression of lung disease.
Distribution of T lymphocyte subsets among different
regions of lung tissue
The distribution of CD4+ T lymphocytes is shown in
Fig. 2A. The number of CD4+ T lymphocytes per
0.1 mm2 in the follicle, perivascular, interstitial, and peri-
bronchial regions were 161.4 ± 89.0, 61.4 ± 30.6, 40.9 ±
12.0, and 25.9 ± 14.2, respectively. The numbers of CD4
+ T cells decreased gradually in the order of the follicle,
perivascular, interstitial, and peribronchial regions. The
differences in cell counts between each of two different






































Fig. 2 a Distribution of CD4+ T lymphocytes in different regions of lung tissue. The different in CD4+ cell counts between any two regions were
statistically significant (p < 0.001). b Distribution of CD8 + T lymphocytes in different regions of lung tissue. CD8+ cell in follicles were much more
than those in each of the other three regions (p < 0.001)








CD4+ T lymphocytes (number/0.1 mm2)
Follicle region 163.37 ± 89.58 159.69 ± 94.36 161.93 ± 68.14 0.990
Perivascular region 78.12 ± 34.79 49.74 ± 22.42 53.10 ± 18.17 0.003*
Interstitial region 40.85 ± 12.66 39.54 ± 11.52 38.48 ± 13.97 0.894
Peribronchial region 27.53 ± 15.60 25.70 ± 13.82 20.10 ± 8.84 0.575
CD8+ T lymphocytes (number/0.1 mm2)
Follicle region 123.11 ± 77.81 72.62 ± 26.37 110.74 ± 36.94 0.006
Perivascular region 57.51 ± 23.43 38.91 ± 17.50 52.60 ± 29.89 0.011
Interstitial region 57.96 ± 39.81 36.26 ± 17.53 43.83 ± 18.69 0.037
Peribronchial region 39.11 ± 22.52 27.80 ± 16.27 29.40 ± 12.50 0.111
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The distribution of CD8+ T lymphocytes (Fig. 2B) was
similar to that of CD4+ T lymphocytes. The numbers of
CD8+ T lymphocytes per 0.1 mm2 in perivascular (47.6 ±
22.7), interstitial (45.7 ± 30.1), and peribronchial (32.5 ±
19.3) regions were not significantly different (p = 0.561).
The number of lymphocytes in follicles (96.3 ± 58.4) were
much greater than those in each of the other three regions
(all p < 0.001).
Distribution of CD4+ and CD8+ T lymphocytes among
NSIP subtypes
We analyzed NSIP subtypes as follows: 22 cellular, 28
mixed, and five fibrotic. The distribution of CD4+ and
CD8+ T lymphocytes in these subtypes is summarized
in Table 4. Perivascular infiltration with CD4+ T
lymphocytes was more prominent in patients with the
cellular pattern compared with those with the mixed or
fibrotic pattern. There was no significant difference in
the number of infiltrating CD8+ T lymphocytes among
the four anatomical regions.
The numbers of CD4+ and CD8+ T lymphocytes cells
in the CTD-NSIP (n = 21), NSIP-Ab (+) (n = 14), and
NSIP-Ab (−) (n = 20) groups were not significantly dif-
ferent in each of the four anatomical regions (Table 5).
T lymphocyte subsets in lung tissue and improved CT
findings
After undergoing therapy for 1 year, 25 patients (20
cellular and five mixed patterns) achieved a 50 % im-
provement in GGO and reticular opacity (CT-group










Follicle region 181.5 ± 87.2 155.4 ± 110.7 144.4 ± 73.1 0.401
Perivascular region 70.2 ± 26.8 54.5 ± 25.4 51.2 ± 27.0 0.061
Interstitial region 42.9 ± 12.5 38.2 ± 10.9 38.15 ± 12.20 0.372
Peribronchial region 28.8 ± 13.4 25.6 ± 13.3 26.3 ± 16.1 0.989
CD8+ T lymphocytes
(number/0.1 mm2)
Follicle region 107.9 ± 72.2 102.4 ± 26.1 107.8 ± 50.9 0.139
Perivascular region 59.5 ± 23.7 46.6 ± 17.4 42.7 ± 19.8 0.115
Interstitial region 45.7 ± 23.9 33.3 ± 19.5 54.2 ± 39.0 0.139
Peribronchial region 36.0 ± 21.6 30.2 ± 15.7 30.4 ± 19.4 0.579




Fig. 3 Correlation of T lymphocytes in different regions of tissue and prognosis of NSIP. Group 1: an improvement of ground-glass opacity and reticular
opacity over 50 % on HRCT; Group 2: the lesions were still present but decreased between 30–50 % on HRCT; Group 3: the lesions were reduced less
than 30 % on HRCT. There is statistical significance of CD4+ lymphocytes perivascular infiltrates among three groups (p = 0.001)
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1). The lesions of 14 patients (all mixed pattern) de-
creased between 30 % and 50 % (CT-group 2). The
lesions of 14 patients (nine mixed and five fibrotic
patterns) were reduced by <30 % (CT-group 3). The
number of CD4+ T lymphocytes in perivascular tissue
in the CT-group 1 was significantly greater compared
with those of other two CT-groups (76.5 ± 33.9 vs
49.5 ± 17.3, p = 0.009; 76.5 ± 33.9 vs 43.9 ± 18.4, p =
0.002) (Fig. 3), but not in the other anatomical re-
gions. There was no correlation between the number
of CD8+ T lymphocytes and the improvement HRCT
findings.
T lymphocyte subsets of lung tissue and pulmonary
function tests
Cox multivariate regression analysis revealed that after
12 months of follow-up, FVC was an independent factor
for survival (HR, 0.828; 95 % CI, 0.692–0.992; p = 0.040)
(Additional file 1: Table S1). There was a marginal correl-
ation of FVC with the number of perivascular CD4 cells
(Fig. 4). Among 55 patients, 21 (11 cellular and 10 mixed
patterns) achieved an improvement of FVC >10 % (FVC-
group 1). No correlation between perivascular CD4 infiltra-









Perivascular CD4 Tlymphocytes  
Fig. 4 The relationship between perivascular CD4 infiltration and
12 months Follow-up FVC (p = 0.059, r = 0.256)

































FVC-group2 FVC-group3 FVC-group1 FVC-group2 FVC-group3 FVC-group1 FVC-group2 FVC-group3 FVC-group1 FVC-group2 FVC-group3
FVC-group1 FVC-group2 FVC-group3 FVC-group1 FVC-group2 FVC-group3 FVC-group1 FVC-group2 FVC-group3 FVC-group1 FVC-group2 FVC-group3
P=0.609 P=0.001 P=0.067 P=0.062
P=0.136 P=0.474 P=0.871 P=0.359
Fig. 5 The relationship between CD4 T lymphocytes in perivascular regions of tissue and prognosis of FVC in NSIP patients. There are significant
difference among three groups, p = 0.001.FVC-Group1 vs FVC-Group2 p = 0.056; FVC-Group1 vs FVC-Group3 p = 0.000; FVC-Group2 vs FVC-Group3
p = 0.054. FVC-group 1: an improvement of FVC over 10 % after 12 months treatment. FVC-group 2: FVC improved between 10 and −10 % after
12 months treatment. FVC-group 3: FVC worsen over −10 % after 12 months treatment
r=0.270
p=0.046
Fig. 6 CD4+ T lymphocytes perivascular infiltration were closely
related to survival time in NSIP patients. Correlation coefficients were
calculated using the Spearman rank method
Qin et al. BMC Pulmonary Medicine  (2015) 15:127 Page 7 of 10
file 2: Figure s2) and DLCO after 12 months follow up
(p=0.134, r=-0.205) (Additional file 3: Figure S2).
Nineteen patients (eight cellular, nine mixed, and two fi-
brotic patterns) achieved improved FVC between 10 %
and −10 % (FVC-group 2). The FVC values of 15 patients
(three cellular, nine mixed, and three fibrotic patterns) de-
creased greater than −10 % (FVC-group 3). The number
of CD4+ T lymphocytes that infiltrated perivascular tissue
in FVC-group 1 was significantly greater than those of the
other two groups (77.9 ± 31.5 vs 63.0 ± 23.1, p = 0.056;
77.9 ± 31.5 vs 46.5 ± 12.5, p = 0.001) (Fig. 5).
The densities of CD4+ and CD8+ T lymphocytes T
that infiltrated other anatomical compartments was not
significantly associated with pulmonary function tests.
The number of CD4+ T lymphocytes infiltrating
perivascular tissue influences survival
Cox multivariate regression analysis considered age, sex,
and numbers of CD4+ and CD8+ T lymphocytes infil-
trating the lungs, and lung function tests (first visit and
after 1 year of follow-up). The results revealed that peri-
vascular infiltration of CD4+ T lymphocytes (HR, 0.939;
95 % CI, 0.883–0.999; p = 0.048) was an independent fac-
tor for survival (Additional file 1: Table S1).
The densities CD4+ T lymphocytes infiltrating perivas-
cular tissues of all patients were significantly associated
with survival time (r = 0.270, p = 0.046) (Fig. 6) compared
with those in other anatomical compartments. Further,
patients with a much higher density of CD4+ T lympho-
cytes (≥61 cells/0.1 mm2) in the perivascular compartment
survived longer (log-rank test, 4.58; p = 0.040) (Fig. 7). The
cutoff value was determined using the ROC curve, and
the AUC for patients’ survival was 0.79 (sensitivity 0.615,
specificity 0.710).The densities of CD4+ and CD8+ T lym-
phocytes infiltrating other anatomical compartments were
not significantly associated with survival time.
The most important finding of the present study was
that the number of CD4+ T lymphocytes that infiltrated
perivascular tissue correlated significantly with the prog-
nosis of NSIP.
Immunohistochemical analyses revealed the T lympho-
cyte subsets infiltrated not only lymphoid follicles and inter-
stitial regions, but perivascular and peribronchial regions as
well, which is consistent with the findings of our previous
study [7]. In this study, we did not detect a significant differ-
ence in T lymphocyte density among cellular, mixed, and fi-
brotic patterns among the same tissues analyzed here. The
small number of patients with the fibrotic pattern might ac-
count for these findings, although we show here that there
were more lymphocytes in patients with the cellular than
with the fibrotic pattern. In contrast, in the present study,
we found a correlation between the infiltration of perivascu-
lar tissue with CD4+ Tcells with prognosis.
The predictors of prognosis of patients with ILD are the
results of the pulmonary function test [18–20] and all-
cause mortality [27–31]. In the present study, we com-
bined them [29] to analyze perivascular CD4+ T lympho-
cyte infiltration and clinical prognosis. FVC consistently
predicts the mortality of patients with IPF [17–20, 32] and
is considered the best marker of chronic disease progres-
sion. FVC data now serve as the preferred primary end-
point in trials of therapies IPF [33].
In the present study, we show that FVC was an inde-
pendent predictor of survival, which is consistent with the
results of previous studies [32, 34–37]. When we classified
patients according to the change of FVC after the 12-
month follow-up, we found that higher numbers of perivas-
cular CD4+ T lymphocytes correlated with improved FVC.
In the present study, all-cause mortality was 23.6 %.
Cox multivariate regression analysis revealed that peri-
vascular CD4+ T lymphocyte infiltration was an inde-
pendent predictor of survival. Survival time correlated
with the number of perivascular CD4+ T lymphocytes.
Patients with higher numbers of perivascular T lympho-
cytes in the perivascular region have a better prognosis.
The accumulation of T lymphocytes in tissue is con-
sidered a cell-mediated immune reaction to bodily injury
[38], particularly in patients with immune dysfunction
[39]. The accumulation of perivascular CD4+ T lympho-
cytes occurs in patients with cutaneous lichen planus
[40] and in the muscle tissue of patients with dermato-
myositis [41]. Some studies found that T cells might be
involved in the pathogenesis of interstitial lung disease.
For example, the levels of CXCL9, CXCL10, and
CXCL11 in bronchoalveolar lavage fluid indicate that
p=0.040
(months)
Fig. 7 Kaplan-Meier survival curve for 55 NSIP patients grouped by
the cell density of CD4 in small vessel region. Green line: ≥61 cells/
0.1 mm2. Blue line: < 61 cells/0.1 mm2. There is a significant
difference (log-rank test: 4.58, p = 0.04) between the groups
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lung fibroblasts induce a Th1-type immune response in
patients with NSIP [42].
In an animal model of lung injury, perivascular CD4+
T lymphocytes accumulate in lung tissue [43, 44]. In pa-
tients with interstitial pneumonia caused by graft-
versus-host disease, interstitial pneumonitis develops
primarily from the dissemination of perivascular CD4+
T lymphocytes infiltrates [45]. Immunosuppressive
agents such as cyclophosphamide suppress inflammation
caused by perivascular T lymphocytes by reducing the T
lymphocyte population and ameliorating T lymphocyte
function [46]. These findings, taken together with those
of the present study, suggest that perivascular infiltration
of CD4+ T lymphocytes contributes to the pathogenesis
of NSIP. If CD4+ T cells are involved in ILD, treating
patients with anti-T cell-specific immunosuppressants
such as FK506 and anti-TNF-α antibodies may be justi-
fied. For example, patients with ILD, particularly those
with CTD-ILD, respond to these agents, [47, 48].
It is very unlikely that lung biopsies will be performed
solely to count T-cells when pulmonary function tests
and other less invasive measures are available. The im-
plication of our findings related to therapy is that they
provide an answer to the question of why anti-T cell
treatment is beneficial for patients with ILD.
We recognize that our study is limited by its retro-
spective design, and B lymphocyte and other inflamma-
tory cells were not investigated. However, to our
knowledge, this is the first study to evaluate the relation-
ship between perivascular infiltration of CD4+ T cells
and the prognosis of patients with NSIP.
In conclusion, we show here that perivascular infiltra-
tion of CD4+ T cells correlated significantly with prog-
nosis and survival. The underlying mechanisms require
further study.
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